“`html
AI is revolutionizing drug development, reducing the typical timeline of 10 to 15 years to as little as 3 to 6 years. This shift will allow pharmaceutical companies to enjoy monopoly pricing for an extended period, significantly boosting profits from new medications.
With the introduction of faster drug discovery cycles, companies like Alnylam Pharmaceuticals, a leading player in RNA interference therapies, are expected to benefit greatly. The BlackRock Health Sciences Term Trust (BMEZ), which invests in such companies, is currently trading at a 13% discount to its net asset value, aligning investors to capitalize on the anticipated growth in the sector.
Analysts expect that the combination of AI and favorable regulatory changes will lead to more drug candidates approved, enhancing cash flow for pharmaceutical firms as they monetize successful drugs faster than before.
“`
